How to Dose Tesamorelin

Key Takeaways

• Start at 0.25 mg subcutaneously once daily and titrate up to a 2 mg/day maximum; run a cycle of 8–12 weeks on, then 4 weeks off
• Evening injection 30–60 minutes before sleep aligns the peptide peak with the body's largest endogenous GH pulse during slow-wave sleep
• The 32 mg pen is pre-filled and dials the dose directly — no reconstitution and no bacteriostatic water
• Rotate injection sites across four abdominal and hip zones, moving at least 2 cm from the previous puncture and avoiding the same quadrant within 96 hours
• Store at 2–8 °C, protected from light; 24 months unopened, 12 months once first pierced, up to 30 days at room temperature (≤30 °C) if refrigeration isn't available
• Tesamorelin is unlicensed in the UK as of 2026 and carries no BNF monograph; it is supplied for research use only

---

The product protocol starts at 0.25 mg subcutaneously once daily and titrates upward to a 2 mg/day maximum, administered into the abdomen and ideally timed to exploit the slow-wave sleep GH pulse that accounts for roughly 70% of 24-hour GH output [7]. Starting low reduces injection-site reactions and allows early detection of fluid retention or glucose dysregulation. Run the cycle for 8–12 weeks, then take 4 weeks off.

For clinical-trial reference, Egrifta / Egrifta SV used a fixed 2 mg/day (or 1.4 mg/day) dose in HIV-lipodystrophy studies [3][4][5] — that is the trial anchor, separate from the titrated product protocol above.

Tesamorelin is unlicensed in the UK as of 2026 and carries no BNF monograph [8][9].

What Is Tesamorelin and How Does It Work?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-terminus to resist dipeptidyl peptidase-IV cleavage and extend plasma stability versus native GHRH(1-44) [1]. It binds pituitary GHRH receptors on somatotrophs, triggering endogenous GH release and a downstream rise in hepatic IGF-1, rather than supplying exogenous hormone directly [1][4].

That mechanistic distinction matters for protocol design. Unlike somatropin, which floods the circulation with recombinant GH and suppresses the hypothalamic-pituitary feedback loop, tesamorelin preserves pulsatile GH secretion and remains subject to negative feedback from somatostatin and IGF-1 [1]. The practical consequence is that GH peaks track the body's own circadian rhythm, which is why injection timing relative to slow-wave sleep onset is non-trivial rather than cosmetic.

Pharmacokinetically, tesamorelin has a short plasma half-life of roughly 25–30 minutes after subcutaneous dosing, yet drives prolonged downstream IGF-1 elevation that supports once-daily administration [1][2]. The reference clinical dose comes from the 2010 FDA approval of Egrifta at 2 mg/day SC for HIV-associated visceral adiposity, based on the Falutz et al. NEJM 2007 trial which reported a ~15% VAT reduction versus placebo at 26 weeks [7][2]. That 2 mg figure is the literature anchor against which the modern 1.4 mg Egrifta SV regimen is calibrated [3][4].

For researchers comparing GHRH analogues against GHRP combinations, see CJC-1295 vs Ipamorelin.

Tesamorelin Dosing Protocol at a Glance

The product protocol starts at 0.25 mg subcutaneously once daily and titrates upward to a 2 mg/day maximum, run as an 8–12 week cycle followed by 4 weeks off. The table below sets out the steps.

For clinical-trial reference only, Falutz et al. (NEJM 2007) and the Egrifta / Egrifta SV label used a fixed 2 mg/day (or 1.4 mg/day) dose in HIV-lipodystrophy studies [1][2] — separate from the titrated product protocol above.

Tesamorelin is dosed once daily, typically in the evening to align the ~25–30 minute pharmacokinetic peak with slow-wave sleep GH pulses [1][2]. Start at 0.25 mg/day and titrate gradually toward the 2 mg/day maximum, running an 8–12 week cycle before a 4-week break. Researchers stacking with GHRPs should compare against how to dose CJC-1295 + Ipamorelin before combining agents.

Why Evening Dosing Matters: The GH-Pulse Rationale

Evening dosing aligns the tesamorelin peak with the largest endogenous GH pulse of the 24-hour cycle, which occurs at the onset of slow-wave sleep (SWS). Van Cauter et al. (Sleep, 2000) reported that approximately 70% of daily GH secretion in healthy adults is released during nocturnal SWS, with the dominant pulse tightly coupled to the first SWS episode roughly 60–90 minutes after sleep onset [1]. This is the physiological window of maximum somatotroph sensitivity.

The pharmacokinetics make the timing tractable. Tesamorelin has a terminal plasma half-life of roughly 25–30 minutes after subcutaneous injection [2][3]. Injecting 30–60 minutes before sleep places peak GHRH-receptor occupancy at the pituitary in the same window the somatotrophs are physiologically primed to fire. The exogenous stimulus reinforces a pulse that's already programmed rather than provoking one out of phase.

Morning dosing inverts that logic. Post-awakening, the GH axis sits in a somatostatin-dominant trough, with elevated cortisol and rising IGF-1 negative feedback. A GHRH analogue delivered into that state produces a smaller, more blunted pulse for the same milligram dose, with no SWS amplification to compound the downstream IGF-1 response. No controlled head-to-head trial of AM versus PM tesamorelin exists in the published literature, but the mechanistic case for evening administration underpins the pre-sleep convention used in the Falutz NEJM 2007 programme and carried into the current Egrifta SV label [4][7].

Practical timing window

Researchers running a GHRH plus GHRP stack should apply the same circadian logic; see CJC-1295 vs Ipamorelin for the receptor-level distinction before scheduling co-administration.

Dialling the 32 mg Tesamorelin Pen

The Body Pharm 32 mg tesamorelin pen is pre-filled and ready to dose — there is no powder to reconstitute, no bacteriostatic water, and no volume to calculate on a syringe. You set the dose directly on the dial and inject. The 32 mg total is held in a 3 mL cartridge; because you read the dose off the dial, the internal concentration is a manufacturing figure, not one you dose against.

Step-by-step procedure

1. Temperature equilibration. Remove the pen from the fridge 20–30 minutes before use. Cold solution injected straight from refrigeration is reported to sting more.
2. Attach a fresh pen needle (29–31 G) and discard the seal.
3. Prime. Dial a small test amount and depress until a bead forms at the needle tip, clearing air from the line. Do this on first use and after any needle change.
4. Dial the dose. Set the dial to the target dose (0.25 mg to start, titrating up to the 2 mg/day maximum) and inject subcutaneously.
5. Inspect before use. The solution should be clear and colourless. Discard if cloudy, yellow-tinged, or showing particulate matter.
6. Log and store. Record the dose, site and date; recap and return the pen to 2–8 °C.

Because the pen doses in milligrams on the dial, there is no draw-up volume or U-100 conversion to work out.

In-use handling

The pen is pre-filled, so there is no post-reconstitution window to track. Store it at 2–8 °C between doses; unopened it keeps for 24 months, and once first pierced (first use) it should be used within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Discard any pen showing cloudiness, discolouration or particulate.

For researchers planning a GHRH plus GHRP combination after this protocol, the receptor-level rationale is in CJC-1295 vs Ipamorelin, with stack-specific dosing covered in how to dose CJC-1295 + Ipamorelin.

Reported Subcutaneous Administration Parameters

Published protocols and clinical-technique literature describe subcutaneous administration of tesamorelin into abdominal, thigh, or lateral hip fat using a short insulin-gauge needle, with a shallower angle (approximately 45°) reported for leaner subjects (visible abdominal definition, BMI roughly under 22) and a steeper angle (approximately 90°) where subcutaneous depth exceeds roughly 10 mm. The sequence below summarises the administration steps documented in the literature for daily 1.4–2 mg doses dialled from the pre-filled pen.

1. Hand hygiene. Standard aseptic technique in the literature calls for washing hands with soap and warm water for at least 20 seconds before handling the vial or pen.
2. Site preparation. Protocols describe swabbing the injection site with a 70% isopropyl alcohol prep pad in a single outward spiral, allowing roughly 10 seconds to air-dry, since injecting through wet alcohol is reported to sting and to affect the peptide at the entry tract.
3. Skin fold. A 2–3 cm fold of skin is typically pinched between thumb and forefinger to lift the subcutaneous layer off underlying muscle.
4. Needle angle. Reported angles range from approximately 45° for leaner subjects to approximately 90° where more subcutaneous tissue is present, angle logic comparable to that described for insulin-pen technique in general diabetes-care literature.
5. Administration rate. Slow, steady administration over 3–5 seconds is associated in the literature with lower local pressure and reduced likelihood of a wheal, compared with faster boluses.
6. Withdrawal. Protocols report withdrawing the needle at the angle of insertion, releasing the skin fold, and applying gentle pressure with dry gauze for 5–10 seconds; rubbing the site is associated with dispersal of the depot and increased bruising.
7. Sharps disposal. Standard UK clinical-waste handling requires used needles to go directly into a BS 7320-compliant sharps bin; UK pharmacies generally accept full bins for incineration.

Site rotation pattern

Rotate clockwise across four zones to prevent lipohypertrophy and absorption drift: upper-left abdomen (≥5 cm lateral to the navel), upper-right abdomen, right lateral hip/outer thigh, left lateral hip/outer thigh. Move at least 2 cm from the previous puncture within a zone, and do not reuse the same quadrant within 96 hours. Abdominal sites give the most reproducible absorption for GHRH analogues; thigh and hip serve as rotation relief rather than primary sites.

Storage and Stability: Keeping Tesamorelin Potent

Tesamorelin is a heat- and light-sensitive peptide, so refrigerated, light-protected storage is the default from delivery to final dose. The pen is pre-filled, so there is no reconstitution step and no separate post-reconstitution window to track.

Store the pen at 2–8 °C, protected from light, and never freeze it. Unopened shelf life is 24 months. Once first pierced (first use), use it within 12 months. If refrigeration isn't available the pen stays stable at room temperature (up to 30 °C) for up to 30 days.

Discard the pen immediately on any of the following: cloudiness, visible particulates, yellowing or other colour shift, or a frozen-then-thawed history. Peptide aggregation is not always visible, so a pen that has cycled through warm transit beyond the room-temperature allowance should be considered compromised even if it looks clear.

Where a GHRH + GHRP stack is run alongside tesamorelin, the same cold-chain rules apply to the partner peptide. See the protocol notes in how to dose CJC-1295 + Ipamorelin for stack-specific storage logistics.

Tesamorelin vs Other GHRH Peptides: Where It Fits

Tesamorelin is the only GHRH analogue with a completed Phase III programme and an FDA-approved indication (HIV-associated lipodystrophy, 2 mg/day or 1.4 mg/day for Egrifta SV) [2][4], which gives it the strongest human-data package of any peptide in this class. Sermorelin and CJC-1295 have never cleared that bar; ipamorelin sits in a different mechanistic category entirely.

The mechanistic split matters for protocol design. Tesamorelin and sermorelin both bind the pituitary GHRH receptor and preserve endogenous pulsatility, so they layer cleanly under the somatostatin rhythm. Ipamorelin acts at a separate receptor, which is why GHRH + GHRP stacks produce supra-additive GH release rather than simple summation. For a stack weighed against tesamorelin monotherapy, the comparison in CJC-1295 vs Ipamorelin covers the mechanistic logic, and the protocol detail sits in how to dose CJC-1295 + Ipamorelin.

Research Observations and Reported Outcomes

Published tesamorelin trials at 2 mg/day report a mean ~18% reduction in visceral adipose tissue (VAT) over 26 weeks versus placebo in HIV-associated lipodystrophy cohorts [3]. These are research observations in a specific patient population, not endpoints reproduced or claimed for the Body Pharm research product, and not outcomes anyone should extrapolate to healthy adults without caveat.

The pivotal data come from Falutz et al. (NEJM, 2007), in which 412 HIV-lipodystrophy subjects received 2 mg subcutaneous tesamorelin or placebo once daily for 26 weeks. The between-group difference in VAT at L4–L5 by CT was approximately −13 to −15%, with trunk fat reduction and minimal effect on limb fat [3]. IGF-1 rose significantly from baseline in the active arm, consistent with intact downstream pituitary signalling [3]. Subsequent open-label extension work (Grinspoon et al., reported in the broader HIV-lipodystrophy literature) found that VAT reduction was sustained at 52 weeks in continued-treatment subjects, with discontinuation producing reversal toward baseline [1].

Disclaimer: All figures above describe published research in HIV-lipodystrophy patients. Body Pharm sells tesamorelin for laboratory research use only; no efficacy or safety claim is made for any human application.

Frequently Asked Questions

Can tesamorelin be dosed twice daily?

No published clinical trial uses a split twice-daily schedule. Given the ~30-minute plasma half-life but prolonged downstream GH/IGF-1 signalling, once-daily dosing is sufficient to drive the desired pulse, and twice-daily administration would risk pituitary desensitisation without efficacy data to justify it.

What time of day should tesamorelin be injected?

Evening, roughly 30–60 minutes before sleep. Van Cauter et al. (2000) reported that approximately 70% of daily GH secretion occurs during slow-wave sleep, with the largest pulse tied to SWS onset [6]. Pre-sleep dosing reinforces that endogenous pulse rather than competing with daytime somatostatin tone.

How long is a typical tesamorelin research cycle?

The product protocol runs an 8–12 week cycle, then 4 weeks off. (The clinical trials ran longer continuous courses — Falutz et al. 26 weeks at a fixed 2 mg/day, extensions to 52 weeks [3] — but that is trial reference, not the product protocol.)

Does tesamorelin need to be cycled?

Yes — the product protocol is 8–12 weeks on, then 4 weeks off. The clinical evidence itself does not mandate cycling (discontinuation reverses VAT changes toward baseline within months [3]), but the research protocol here uses a defined on/off cycle.

How is tesamorelin titrated?

Start at 0.25 mg/day and step up gradually as tolerated to a 2 mg/day maximum — do not exceed 2 mg/day. The low start reduces injection-site reactions and lets fluid-retention or glucose responses show early. 2 mg/day is also the fixed dose that produced the ~15% VAT reduction in the NEJM 2007 trial [3], reached here by titration rather than opened at. Researchers comparing GHRH options against GHRP combinations may find the CJC-1295 vs Ipamorelin comparison useful.

Research Disclaimer and Legal Notice

Notice dated 2026. All Body Pharm UK products, including tesamorelin, are supplied strictly for in vitro research and analytical purposes only. They are not for human or animal consumption, not for use as a medicinal product, and not a substitute for advice from a registered UK clinician.

Tesamorelin holds no UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and has no British National Formulary monograph as of 2026 [1][2]. It is not a licensed medicine in the United Kingdom. Researchers are responsible for compliance with the Human Medicines Regulations 2012 and any institutional or ethical frameworks governing their work.

The dosing parameters discussed throughout this guide describe published clinical-trial regimens; they are not a recommendation for personal use. For adjacent protocol context within this research cluster, see CJC-1295 vs Ipamorelin and how to dose CJC-1295 + Ipamorelin.

Next Steps

Tesamorelin research protocols begin at 0.25 mg/day and titrate gradually to a 2 mg/day maximum, run as an 8–12 week cycle followed by 4 weeks off. A cold chain should be established before delivery arrives, with a sharps disposal route confirmed via a local UK pharmacy. For researchers considering a GHRH plus GHRP stack, CJC-1295 vs Ipamorelin sets out the mechanistic rationale, and how to dose CJC-1295 + Ipamorelin covers combined-agent dosing and timing.

References

1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
2. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
3. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV (pivotal 26-week VAT and IGF-1 data). N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
4. Egrifta / Egrifta SV (tesamorelin) FDA prescribing information and approved-label dosing (1.4 mg / 2 mg once daily). US regulatory label, not a peer-reviewed study (unverified/unlinked).
5. Egrifta SV (tesamorelin) licensed label instruction on reconstitution and immediate use / discard. Regulatory label, not a peer-reviewed study (unverified/unlinked).
6. Claim that ~70% of daily GH is secreted during slow-wave sleep, attributed in-text to Van Cauter et al. (2000). The specific journal/year framing in the prose could not be matched to a verifiable primary record and is left unlinked (unverified).
7. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
8. Tesamorelin UK regulatory status: no MHRA marketing authorisation and no British National Formulary (BNF) monograph as of 2026. Regulatory status note, not a study (unverified/unlinked).
9. Tesamorelin UK regulatory status: no MHRA marketing authorisation and no BNF monograph as of 2026. Regulatory status note, not a study (unverified/unlinked).